Jonathan Luetke Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 405 N Wales Rd, Wales, WI 53183 Phone: 262-968-9570 |
Melissa Haakenson Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 320 W Summit Ave, Wales, WI 53183 Phone: 262-968-6900 |
Dr. Roger Alan Smith Jr., PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 320 W Summit Ave, Wales, WI 53183 Phone: 262-968-6900 Fax: 262-968-3714 |
Dr. Julianne Marie Torres Albizu, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 320 W Summit Ave, Wales, WI 53183 Phone: 262-968-6900 Fax: 262-968-3714 |
Margaret Davies, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 320 W Summit Ave, Wales, WI 53183 Phone: 262-968-6900 |
Carl D Below, R.PH. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 320 W Summit Ave, Wales, WI 53183 Phone: 262-968-6900 Fax: 262-968-3714 |
Dr. Dawn Engelhardt, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 405 N Wales Rd, Wales, WI 53183 Phone: 262-968-9570 |
News Archive
Annual deaths related to heroin and morphine are continuing to drop significantly, falling from 41 per cent of total drug-related deaths in the UK in 2010 to 32 per cent in 2011. Meanwhile, deaths from 'legal highs' - some of which have now been banned - remained steady following a large increase in the previous year.
A natural substance present in red wine, resveratrol, inhibits the formation of inflammatory factors that trigger cardiovascular diseases. This has been established by a research team at the Department of Pharmacology of the University Medical Center of Johannes Gutenberg University of Mainz working in collaboration with researchers of the Friedrich Schiller University in Jena and the University of Vienna.
Patients with severe cases of kidney stones are 26 percent less likely to receive timely treatment when they're admitted to the hospital on the weekend, according to a study by researchers at Loyola Medicine and Loyola University Chicago Stritch School of Medicine.
Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for blinding eye diseases, announced today that the first patient data from the ACU-4429 program were presented during a poster session at The Association for Research in Vision and Ophthalmology (ARVO) 2012 Annual Meeting.
› Verified 1 days ago